- Home
- STTK vs BLUE Comparison
STTK vs BLUE Comparison
Compare STTK & BLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STTK
- BLUE
- Stock Information
- Founded
- STTK 2016
- BLUE 1992
- Country
- STTK United States
- BLUE United States
- Employees
- STTK N/A
- BLUE N/A
- Industry
- STTK Biotechnology: Pharmaceutical Preparations
- BLUE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- STTK Health Care
- BLUE Health Care
- Exchange
- STTK Nasdaq
- BLUE Nasdaq
- Market Cap
- STTK 36.2M
- BLUE 36.9M
- IPO Year
- STTK 2020
- BLUE 2013
- Fundamental
- Price
- STTK $0.84
- BLUE $4.09
- Analyst Decision
- STTK Hold
- BLUE Hold
- Analyst Count
- STTK 4
- BLUE 7
- Target Price
- STTK $3.00
- BLUE $44.60
- AVG Volume (30 Days)
- STTK 305.5K
- BLUE 524.5K
- Earning Date
- STTK 05-01-2025
- BLUE 05-08-2025
- Dividend Yield
- STTK N/A
- BLUE N/A
- EPS Growth
- STTK N/A
- BLUE N/A
- EPS
- STTK N/A
- BLUE N/A
- Revenue
- STTK $5,721,000.00
- BLUE $83,807,000.00
- Revenue This Year
- STTK N/A
- BLUE $218.58
- Revenue Next Year
- STTK N/A
- BLUE N/A
- P/E Ratio
- STTK N/A
- BLUE N/A
- Revenue Growth
- STTK 245.26
- BLUE 184.12
- 52 Week Low
- STTK $0.69
- BLUE $3.56
- 52 Week High
- STTK $11.76
- BLUE $28.60
- Technical
- Relative Strength Index (RSI)
- STTK 44.82
- BLUE 42.76
- Support Level
- STTK $0.73
- BLUE $3.83
- Resistance Level
- STTK $0.90
- BLUE $4.57
- Average True Range (ATR)
- STTK 0.15
- BLUE 0.38
- MACD
- STTK 0.00
- BLUE -0.05
- Stochastic Oscillator
- STTK 19.96
- BLUE 16.51
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
About BLUE bluebird bio Inc.
bluebird bio Inc is a biotechnology company engaged in researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its proprietary lentiviral vector (LVV) gene addition platform. The Company operates in a single segment, focusing on researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases.